報價延遲最少15分鐘:2025/07/17 15:52 EDT
盤後時段
|
||||
|
-- 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.1546
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.37/0.60
|
|
企業價值
331.54M
|
| 資產負債 |
|
每股賬面淨值
2.79
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
22.27M
|
|
每股收益
0.21
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/17 15:52 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat. |
